



**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY  
APPLICANT PTO-1449**

ATTY. DOCKET NO.  
10793/45

SERIAL NO.  
10/032,423

APPLICANT  
A. LEVANON et al.

FILING DATE  
December 31, 2001

GROUP  
1614

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
KAC	5,716,836	February 10, 1998	Suiko			
	5,827,817	October 27, 1998	Larsen et al.			
	6,124,267	September 26, 2000	McEver et al.			
	6,548,636 B2	April 15, 2003	Dragie et al.			
	6,593,459 B1	July 15, 2003	Cummings et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
KAC	WO 93/11778	June 24, 1993					

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
KAC	Hagay, Y., et al., "Function-modulating human monoclonal antibodies against platelet-membrane receptors isolated from a phage-display library" Journal of Thrombosis and Haemostasis, Vol. 1, pp. 1829-1836

EXAMINER	<i>Harold A. Gamelle</i>	DATE CONSIDERED	12/23/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY  
APPLICANT PTO-1449**

ATTY. DOCKET NO.  
10793/45

SERIAL NO.  
10/032,423

APPLICANT  
LEVANON et al.

FILING DATE  
December 31, 2001

GROUP  
1614

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
<i>duplicate</i>	<del>5,716,836</del>	<del>February 10, 1998</del>	<del>Guiko</del>			
<i>KAC</i>	5,720,954	February 24, 1998	Hudziak, et al.			
<i>↓</i>	6,312,694	November 6, 2001	Thorpe, et al.			
<i>↓</i>	2002-0058034	May 16, 2002	Manjunath, et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>KAC</i>	Huo, et al., "Adhesion molecules and atherogenesis," Acta Physiol Scand. 2001, Vol. 173, pp. 35-43
<i>↓</i>	Kamiyama, et al., "Inhibition of platelet GPIIb/IIIa binding to fibrinogen by serum factors: Studies of circulating immune complexes and platelet antibodies in patients with hemophilia, immune thrombocytopenic purpura, human immunodeficiency virus - related immune thrombocytopenic purpura, and systemic lupus erythematosus," J. Lab Clin. Med., (1991) Vol. 117, No. 3, pp. 209-217
<i>↓</i>	Libby, "Atherosclerosis: The New View," Scientific American, May 2002, pp. 28-37
<i>↓</i>	Ma, et al., "Obligatory Requirement of Sulfation for P-Selectin Binding to Human Salivary Gland Carcinoma Acc-M Cells and Breast Carcinoma ZR-75-30 Cells," Journal of Immunology, 2002, Vol. 168, pp. 1690-1696.
<i>↓</i>	Malmberg, et al., "BIAcore as a tool in antibody engineering," Journal of Immunological Methods, 1995, Vol. 183, pp. 7-13
<i>↓</i>	Michelson, et al., "Partial Characterization of a Binding Site For von Willebrand Factor on Glycocalicin," Blood, January 1986, Vol. 67, No. 1, pp. 19-26
<i>↓</i>	Myszka, "Improving Biosensor Analysis," Journal of Mol. Recog., 1999, No. 12, pp. 279-284
<i>↓</i>	Shebuski, et al., "Role of Inflammatory Mediators in Thrombogenesis," JPET, 2002, Vol. 300, No. 3, pp. 729-735
<i>↓</i>	Wang, et al., "Prevention of Intimal Hyperplasia With Recombinant Soluble P-Selectin Glycoprotein Ligand-Immunoglobulin in the Porcine Coronary Artery Balloon Injury Model," JACC, August 2001, Vol. 38, No. 2, pp. 577-582

EXAMINER *Karen A. Ganello*

DATE CONSIDERED *12/23/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## OTHER DOCUMENTS

RECEIVED  
AUG 09 2002  
TECH CENTER 1600/2900

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
KAC	Altschul et al. "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, 1997, vol. 25, no. 17, pp. 3389-3402 ✓
	Bass, et al. "Hormone Phage: An enrichment method for variant proteins with altered binding properties", Proteins: Structure, Function and Genetics, 1990 vol. 8, pp. 309-314 ✓
	Caron et al., "Murine and Humanized Constructs of Monoclonal Antibody M195 (Anti-CD33) for the therapy of acute myelogenous leukemia", Cancer Supplement, Feb. 1, 1994, vol. 73, no. 3, pp.1049-1056 ✓
	Caron et al., "A Phase IB trial of humanized monoclonal antibody M195 (Anti-CD33) in myeloid leukemia: specific targeting without immunogenicity" ✓
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands", Proc. Nat'l. Acad. Sci. USA, August 1990, vol. 87, pp. 6378-6382 ✓
	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules", Science, vol 249, pp. 404-406 ✓
	Griffiths et al., "Isolation of high affinity human antibodies directly from large synthetic repertoires," EMBO Journal, 1994, vol. 13, no. 14, pp. 3245-3260 ✓
	Henkart, "Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules", Immunity, August 1984, vol. 1, pp. 343-346 ✓
	Holliger et al., " "Diabodies": small bivalent and bispecific antibody fragments", Proc. Nat'l. Acad. Sci. USA, July 1993, vol. 90, pp. 6444-6448 ✓
	Hudson et al., "High avidity scFv multimers; diabodies and triabodies", Journal of Immun. Methods, 1999, vol. 231, pp. 177-189 ✓
	Jarvik et al., "Epitope Tagging", Annu. Rev. Genet., 1998, vol. 32, pp. 601-618 ✓
	Jurcic et al., ABSTRACT #2528, Blood, 1992 (10 Suppl. Part 1-2) ✓
	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer", Protein Engineering, 1997, vol. 10, no. 4, pp. 423-433 ✓
	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, Dec. 6, 1990, vol. 348, pp. 552-554 ✓
	McGraw et al., "Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias", Cancer Immunol. Immunotherapy, 1994, vol. 39, pp. 367-374 ✓
	Nissim et al., "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO Journal, 1994, vol. 13, no. 3, pp. 692-698 ✓
	Scott et al., "Searching for peptide ligands with an epitope library", Science, July 27, 1990, vol. 249, pp. 386-390 ✓
	Sgouros et al. ABSTRACT #979, J. Nucl. Med. Vol. 38 (5 Suppl.) ✓
	Sievers et al., ABSTRACT #2246, Blood, vol. 90 (10 Suppl. 1 Part 1) ✓
	Smith, "Filamentous Fusion Phage: Novel expression vectors that displayed cloned antigens on the virion surface", Science, June 14, 1985, vol. 228, pp. 1315-1317 ✓
	Squier et al., "Cell-mediated cytotoxic mechanisms", Current Opinion in Immunology, 1994, vol. 6, pp. 447-452 ✓
	Sun et al., "Antitumour activity of a chimeric antibody against the leucocyte antigen CD48", Cancer Immunol. Immunotherapy, 2000, vol. 48, pp. 595-602 ✓
	Takebe et al., "Src Promoter: an efficient and versatile mammalian cDNA Expression System....", Molecular and Cellular Biology, Jan. 1988, vol. 8, no. 1, pp. 466-472 ✓
	Thompson et al. "A fully human antibody neutralising biologically active human TGFβ2 for use in therapy", J. of Immunol. Methods, 1999, vol. 227, pp. 17-26 ✓
	Tomlinson et al., The repertoire of human germline V <sub>H</sub> segments with different hypervariable loops", J. Mol. Biol., 1992, vol. 227, pp. 776-798 ✓


EXAMINER

*John P. Canello*

DATE CONSIDERED

*12/23/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. 10793/45	SERIAL NO. 10/032,4
	APPLICANT LEVANON et al.	
	FILING DATE December 31, 2001	GROUP 1614

U. S. PATENT DOCUMENTS


EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
KAC	5,168,062	December 1, 1992	Stinski	5	1	1
↓	5,385,839	January 31, 1995	Stinski	5	1	1
↓	6,132,730	October 17, 2000	Thorpe, et al.	5	1	1

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
KAC	Adams, G.P. et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu," British Journal of Cancer (1998) Vol. 77, No. 9, pp. 1405-1412 ✓
↓	Afshar-Kharghan, Vahid et al., "Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region," Blood, Vol. 97, No. 10, May 15, 2001, pp. 3306-3307 ✓
↓	Altman, John D. et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science, Vol. 274, October 4, 1996, pp. 94-96 ✓
↓	Bundgaard, Jens R. et al., "New Consensus Features for Tyrosine O-Sulfation Determined by Mutational Analysis," The Journal of Biological Chemistry, Vol. 272, No. 35, August 29, 1997, pp. 21700-21705 ✓
↓	Clezardin, Philippe et al., "Role of Platelet Membrane Glycoproteins Ib/Ix and IIb/IIIa, and of Platelet α-Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells," Cancer Research, Vol. 53, October 1, 1993, pp. 4695-4700 ✓
↓	Cochran, Jennifer R. et al., "The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers," Immunity, Vol. 12, March 2000, pp. 241-250 ✓
↓	de Kruif, John et al., "Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library," The Journal of Biological Chemistry, Vol. 271, No. 13, March 29, 1996, pp. 7630-7634 ✓
↓	Gasic, Gabriel J. et al., "Antimetastatic Effects Associated with Platelet Reduction," Proc. Natl. Acad. Sci. USA, Vol. 61, 1968, pp. 46-52 ✓
↓	Gilbert, Walter et al., "The LAC Operator is DNA," Proc. Natl. Acad. Sci. USA, Vol. 58, 1967, p. 2415-2421 ✓
↓	Harrison, Jacqueline L. et al., "Screening of Phage Antibody Libraries," Methods in Enzymology, Vol. 267, 1996, pp. 83-109 ✓
↓	Roberts, Jeffrey W. et al., "Lysogenic Induction," Lambda II, Cold Spring Harbor Laboratory, 1983, pp. 123-144 ✓



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
10793/45

SERIAL NO.  
10/032,423

APPLICANT(S) LAZAROVITS et al.

FILING DATE  
December 31, 2001

GROUP  
1614

TECH CENTER 1600/2900

AUG 09 2002

RECEIVED

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME
KAC	5,223,409	6/29/93	Ladner et al.
↓	5,403,484	4/4/95	Ladner et al.
↓	5,427,908	6/25/95	Dower et al.
↓	5,432,018	7/11/95	Dower et al.
duplicate →	<del>5,720,934</del>	<del>2/24/98</del>	<del>Hudziak et al.</del>
KAC	5,763,215	6/9/98	Blumberg et al.
↓	5,795,776	8/18/98	Fischer
↓	5,821,337	10/13/98	Carter et al.
↓	5,843,439	12/1/98	Anderson et al.
↓	5,945,304	8/31/99	Fischer

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
KAC	WO 94/26787	11/24/94	PCT	✓	✓
↓	WO 00/29004	5/25/00	PCT	✓	✓
↓	EP 0 589 877	11/13/96	Europe	✓	✓



JAN 21 2003

TECH CENTER 1600/2900

TECH CENTER 1600/2900

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
KA E	Hudson, Peter J. et al., "Recombinant antibody constructs in cancer therapy," Current Opinion in Immunology, Vol. 11, 1999, pp. 548-557 ✓
	Jurcic, J.G. et al., "Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33)," Blood, 90(suppl.): 504a, 1997 ✓
	Kamiyama, Mikio et al., "Inhibition of Human Platelet Glycoprotein IIB/IIIA Binding to Fibrinogen by Tumor Cell Membrane Ptoeins," Cancer Research, Vol. 53, January 15, 1993, pp. 221-223 ✓
	Karparkin, S. et al., "Role of Adhesive Proteins in Platelet Tumor Interaction in Vitro and Metastasis Formation In Vivo," J. Clin. Invest., Vol. 81, April 1988, pp. 1012-1019 ✓
	Kehoe, John W. et al., "Tyrosine sulfation: a modulator of extracellular protein-protein interactions," Chemistry & Biology, Vol. 7, No. 3, 2000, pp. R57-R61 ✓
	Kieffer, Nelly et al., "Expression of Platelet Glycoprotein Iba in HEL Cells," The Journal of Biological Chemistry, Vol. 261, No. 34, December 5, 1986, pp. 15854- 15862 ✓
	Kipriyanov, Sergey M. et al., "Single-chain antibody streptavidin fusions; Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen," Hum. Antibod. Hybridomas, Vol. 6, No. 3, 1995, pp. 93-101 ✓
	Kishimoto, Tadamitsu et al. (eds.) Leucocyte Typing VI: Proceedings of the Sixth International Workshop and Conference held in Kobe, Japan, 10-14 November 1996, pp. 1218-1219 ✓
	Kostelny, Sheri A. et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers," The Journal of Immunology, Vol. 148, No. 5, March 1, 1992, pp. 1547-1553 ✓
	Marks, James D. et al., "By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage", J Mol. Biol., Vol. 222, 1991, pp.581-597 ✓
	Moore, Kevin L. et al., "Identification of a Specific Glycoprotein Ligand for P-selectin (CD62) on Myeloid Cells," The Journal of Cell Biology, Vol. 118, No. 2, July 1992, pp. 445-456 ✓
	Oleksowicz, Leslie et al., "Characterization of Tumor-Induced Platelet Aggregation: The Role of Immunorelated GPIb and GPIIb/IIIa Expression by MCF-7 Breast Cancer Cells," Thrombosis Research, Vol. 79, No. 3, 1995, pp. 261-274 ✓
	Power, Barbara E. et al., "Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging," Journal of Immunological Methods, Vol. 242, 2000, pp. 193-204 ✓
	Ramachandran, Vishwanath et al., "Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow," Proc. Natl. Acad. Sci. USA, Vol. 98, No. 18, August 28, 2001, pp. 10166-10171 ✓
	Rodgers, Stephen D. et al., "Tyrosine Sulfation Enhances but is not Required for PSGL-1 Rolling Adhesion on P-Selectin," Biophysical Journal, Vol. 81, October 2001, pp. 2001-2009 ✓
	Schmidt, Emmett V. et al., "The Cytomegalovirus Enhancer: a Pan-Active Control Element in Transgenic Mice," Mol. Cell. Biol., Vol. 10, August 1990, pp. 4406-4411 ✓
	Snapp, Karen R. et al., "A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P-and L-Selectin," Blood, Vol. 91, No. 1, January 1, 1998, pp. 154-164 ✓
	Tomlinson, Stephen, "Complement defense mechanism," Current Opinion in Immunology, Vol. 5, 1993, pp. 83-89 ✓
	Varki, A. et al., "P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications," Braz. J. Med. Biol. Res., Vol. 34, No. 6, 2001, pp. 711-717 ✓
	Ward, Christopher M. et al., "Mocarhagin, a Novel Cobra Venom Metalloproteinase, Cleaves the Platelet von Willebrand Factor Receptor Glycoprotein Iba. Identification of the Sulfated Tyrosine/Anionic Sequence Tyr-276-Glu-282 of Glycoprotein Iba as a Binding Site for von Willebrand Factor and $\alpha$ -Thrombin," Biochemistry, Vol. 35, No. 15, 1996, pp. 4929-4938 ✓
	Wu, AM et al., "Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging," Tumor Targeting, Vol. 4, 1999, pp. 47-58 ✓

EXAMINER <i>James A. Gamble</i>	DATE CONSIDERED <i>12/23/04</i>
EXAMINER: initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	